• MK-0812: Unraveling CCR2 Inhibition in Gut–Liver Inflammatio

  2026-05-13

  Explore the scientific foundations of MK-0812 as a potent CCR2 antagonist for monocyte trafficking studies. This article uniquely bridges gut–liver axis mechanisms with advanced applications of MK-0812 in inflammation and steatohepatitis research.

• Elobixibat Hydrate: Advanced IBAT Inhibitor Workflows in GI

  2026-05-13

  Elobixibat hydrate enables high-fidelity modeling of chronic idiopathic constipation and metabolic disorders by selectively targeting the ileal bile acid transporter (IBAT). This guide provides actionable assay parameters, workflow enhancements, and troubleshooting insights, empowering researchers to maximize reproducibility and translational value using APExBIO’s validated compound.

• Paroxetine Mesylate: From SSRI Mechanisms to Translational O

  2026-05-12

  This thought-leadership article explores Paroxetine Mesylate's unique role as a selective serotonin reuptake inhibitor (SSRI) with potent multi-kinase inhibition, bridging neuropharmacology and oncology. It delivers mechanistic insights, evidence-based protocol guidance, and strategic perspectives for translational researchers, while contextualizing recent findings from epilepsy biomarker studies in baboon models and advances in colorectal cancer research.

• Doxorubicin (SKU A3966): Practical Lab Scenarios & Data-Driv

  2026-05-12

  This article provides biomedical researchers, lab technicians, and postgraduates with scenario-based, evidence-backed strategies for using Doxorubicin (SKU A3966) in cell viability and cytotoxicity assays. It addresses common experimental challenges, protocol optimization, and vendor reliability, integrating peer-reviewed findings and practical workflow tips to help scientists achieve reproducible, interpretable results. Explore how APExBIO's Doxorubicin enables robust cancer research outcomes.

• MLKL-Induced Lysosomal Disruption and Cathepsin B in Necropt

  2026-05-11

  This article reviews recent findings demonstrating that MLKL polymerization at the lysosomal membrane induces membrane permeabilization, triggering the release of cathepsin B and driving necroptotic cell death. The study reveals critical mechanistic links between necroptosis, lysosomal biology, and the functional role of cathepsin B, with implications for targeted pathway dissection in cell death and disease research.

• Cell Cycle Assay Kit (K2263): Precision Cell Cycle Analysis

  2026-05-11

  The Cell Cycle Assay Kit (Catalog No. K2263) enables precise and reproducible analysis of cell cycle phases G0/G1, S, and G2/M via propidium iodide staining and flow cytometry. The kit facilitates accurate detection of cell proliferation and apoptosis, supporting advanced research in cancer biology and cell cycle progression analysis.

• Cy5 TSA Fluorescence System Kit: Elevating IHC Sensitivity

  2026-05-10

  Unlock ultrasensitive detection of low-abundance targets with the Cy5 TSA Fluorescence System Kit. This article details practical workflows, troubleshooting strategies, and cutting-edge use cases—anchored by real evidence from cancer metabolism research—to help labs achieve reliable, high-resolution fluorescent labeling in immunohistochemistry and in situ hybridization.

• CA-074 and Cathepsin B Inhibition: Mechanistic Insights for

  2026-05-09

  Explore how the cathepsin B inhibitor CA-074 advances cancer metastasis and neurodegeneration studies by uniquely integrating MLKL-driven necroptosis mechanisms with practical assay recommendations. This article delivers deep scientific context and actionable guidance for researchers.

• Paroxetine Mesylate (SKU C8698): Reliable Solutions for Cell

  2026-05-08

  This article examines real lab challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how Paroxetine Mesylate (SKU C8698) addresses data reproducibility and multi-target inhibition. Scenario-driven Q&A highlights evidence-backed protocol parameters and vendor reliability, providing practical insights for scientists optimizing workflows with this selective serotonin reuptake inhibitor.

• (-)-JQ1: Precision Negative Control for BET Bromodomain Stud

  2026-05-08

  (-)-JQ1 is the definitive JQ1 stereoisomer used as an inactive control in BET bromodomain inhibition research, setting a new benchmark for assay specificity and data reproducibility. Its robust use in epigenetics and cancer biology workflows enables researchers to rigorously distinguish on-target from off-target effects, driving high-confidence insights into BRD4-dependent mechanisms.

• Influenza Hemagglutinin (HA) Peptide: Precision Tag for Adva

  2026-05-07

  The Influenza Hemagglutinin (HA) Peptide enables highly specific, reproducible detection and isolation of HA-tagged proteins in even the most challenging immunoprecipitation and exosome workflows. Unique solubility characteristics and competitive antibody binding make it a preferred tool for robust, quantitative molecular biology applications.

• MLKL-Induced Lysosomal Permeabilization Drives Necroptosis v

  2026-05-07

  Recent research uncovers that polymerized MLKL translocates to lysosomal membranes, inducing their permeabilization and subsequent release of cathepsin B, which is essential for necroptosis execution. Chemical inhibition or knockdown of cathepsin B significantly protects cells from necroptotic death, highlighting a critical mechanistic link and providing new avenues for targeted research.

• Merimepodib (VX-497): Precision IMPDH Inhibition in Antivira

  2026-05-06

  Merimepodib (VX-497) empowers translational researchers with noncompetitive, oral inhibition of IMPDH, enabling precise dissection of guanine nucleotide biosynthesis in cancer, immunology, and virology models. Leveraging recent breakthroughs in metabolic targeting, VX-497 stands out for its validated efficacy and workflow flexibility across cell types and disease paradigms.

• Selective β1 Blockade Preserves Hematopoietic Regeneration P

  2026-05-06

  This study demonstrates that nonselective β-adrenergic receptor inhibitors, but not selective β1-blockers, impair hematopoietic recovery after hematopoietic cell transplantation in mice and humans. Findings highlight the significance of β-blocker selectivity for post-transplant engraftment outcomes and inform best practices for cardiovascular therapy in hematopoietic contexts.

• BMAL1 Suppresses Endothelial Apoptosis via STAT6 Repression

  2026-05-05

  This study identifies BMAL1 as a critical transcriptional repressor of endothelial cell apoptosis, acting through direct regulation of STAT6. These findings provide mechanistic insight into angiogenesis and suggest new therapeutic avenues for corneal neovascularization.

11304 records 1/754 page Next 12345 下5页 Last page